1. Overview
Gamma-glutamyl transferase (GGT) is a microsomal enzyme widely distributed in the body but predominantly found in the liver and biliary epithelium. It plays a key role in the metabolism of glutathione, a major intracellular antioxidant, by catalyzing the transfer of the γ-glutamyl group. Through this function, GGT contributes to cellular defense against oxidative stress, amino acid transport, and detoxification of drugs and xenobiotics.
Clinically, GGT is a sensitive marker of hepatobiliary disease. Serum GGT levels rise in liver and bile duct disorders, making it a valuable test in liver function assessment. Importantly, GGT is used to differentiate hepatobiliary causes of elevated alkaline phosphatase (ALP) from bone-related causes, as GGT increases specifically in hepatobiliary conditions. It is also widely utilized as a marker of chronic alcohol consumption and occult alcoholism.
2. Symptoms
GGT elevation itself does not produce symptoms; clinical manifestations arise from the underlying liver or biliary disorder. Common symptoms associated with conditions showing elevated GGT include fatigue, weakness, jaundice, loss of appetite, abdominal pain or swelling, nausea, and vomiting. These features reflect hepatocellular injury, cholestasis, or systemic effects of liver dysfunction.
3. Causes
Elevated GGT levels occur in a wide range of hepatic and systemic conditions. Common causes include chronic alcohol use, cholestasis due to bile duct obstruction, hepatitis, liver cirrhosis, primary biliary cirrhosis, hepatocellular injury, and liver ischemia. GGT is also increased in drug-induced liver injury, particularly with enzyme-inducing medications such as acetaminophen, carbamazepine, phenytoin, phenobarbital, and certain hepatotoxic agents.
Non-hepatic causes associated with raised GGT include diabetes mellitus, obesity, smoking, cardiovascular disease, congestive cardiac failure, pancreatic disease, lung disease, metastatic liver disease, and malignancies, especially liver-related cancers. Because GGT is involved in oxidative stress pathways, elevated levels may also reflect metabolic syndrome and increased cardiovascular risk.
4. Risk Factors
Risk factors for elevated GGT include excessive alcohol consumption, use of hepatotoxic or enzyme-inducing drugs, obesity, smoking, diabetes, metabolic syndrome, and advancing age. Patients with known liver disease, bile duct obstruction, or chronic inflammatory conditions are at increased risk.
GGT levels may also be influenced by medications such as oral contraceptive pills and clofibrate, which can decrease levels, and by recent alcohol intake, which markedly increases enzyme activity. Accurate interpretation requires consideration of clinical history, medication use, and lifestyle factors.
5. Prevention and Clinical Management
GGT testing is indicated in several clinical scenarios, including evaluation of elevated ALP to determine liver versus bone origin, detection and monitoring of chronic alcohol use, assessment of suspected drug-induced hepatotoxicity, screening for hepatobiliary disease, and follow-up of known liver disorders.
For sample collection, patient age and sex must be noted, and clinical history is essential. Patients are advised to stop medications that may affect GGT levels at least 48 hours before blood collection when clinically feasible. A blood sample is collected in a plain red-capped tube, serum is separated promptly, and an aliquot of at least 1.0 mL is sent to the laboratory within two hours.
Laboratory estimation of GGT is performed using spectrophotometry, colorimetry, enzymatic activity assays, hemolyzed whole blood methods, or immunoassays. The normal reference range is approximately 10–40 U/L. Levels above 40 U/L suggest liver disease, alcohol use, or bile duct obstruction, while levels exceeding 100 U/L indicate acute or chronic liver disease or heavy alcohol consumption.
Clinically, GGT is best interpreted in conjunction with other liver enzymes such as ALT, AST, and ALP. Elevated GGT with elevated ALP strongly suggests hepatobiliary pathology. GGT is particularly useful in monitoring alcoholic liver disease, as declining levels reflect abstinence and are valuable in relapse monitoring.
Beyond liver disease, elevated GGT has prognostic significance in cardiovascular disease, cancer risk, and metabolic syndrome, showing a dose-response relationship with all-cause mortality. However, GGT is not disease-specific and must always be interpreted in the clinical context.
Advantages of GGT testing include early detection of liver damage, differentiation between liver and bone disease, cost-effectiveness, low risk, and broad clinical utility. Limitations include a lack of specificity, the influence of lifestyle and medications, and the need for correlation with other laboratory findings and clinical assessment.
